SCHEMBL12898685

SCHEMBL12898685

Clc1ccc(CNc2ccc(Cc3c[nH]c4ccccc34)c(Cl)n2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 5/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPT P10636 3/20 0.48
AHR P35869 1/20 0.48
GPR84 Q9NQS5 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HPGD P15428 1/20 0.47
CYP2C9 P11712 1/20 0.44
GABRP O00591 1/20 0.44
GABRD O14764 1/20 0.44
POLB P06746 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266664 0.84 CSF1R (0.55) CYP1A2CYP3A4GPR84CYP2C9POLB
SCHEMBL5774387 0.76 MEN1 (0.74) CYP1A2CYP3A4MEN1KMT2AMAPT
SCHEMBL1266685 0.74 CYP1A2 (0.67) CYP1A2CYP3A4GPR84CYP2C9CYP2C19
SCHEMBL878819 0.74 CYP1A2 (0.55) CYP1A2CYP3A4GPR84CYP2C9HTR6
SCHEMBL2180397 0.74 CSF1R (0.53) CYP1A2CYP3A4GPR84CYP2C9POLB
SCHEMBL1882003 0.73 CYP3A4 (0.59) CYP1A2CYP3A4GPR84CYP2C9DRD3
SCHEMBL12898693 0.73 CYP2C19 (0.59) CYP3A4MEN1KMT2ACYP2C9GABRP
SCHEMBL1267479 0.72 CYP3A4 (0.80) CYP1A2CYP3A4CYP2C9DRD3CYP2C19
SCHEMBL1267508 0.72 CYP3A4 (0.63) CYP1A2CYP3A4GPR84CYP2C9CYP2C19
SCHEMBL17117861 0.70 MC5R (0.71) MEN1KMT2AMAPTHPGDHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US disclosed
US-7893075-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON, INC. (US) 2011-02-22 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 CYP1A2 4297/4885CYP3A4 3847/4885MEN1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.